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Are Lymphoblastoid Cell Lines Suitable to Study
Increased SMN Gene Expression by Histone Deacetylase
Inhibitors?*

Hayat ERDEM YURTER1
Aim: In this preliminary study, we aimed to analyze the effect of sodium butyrate (NB) and phenylbutyrate
(PB), belonging to the class of histone deacetylase (HDAC) inhibitors, on lymphoblastoid cell lines established
from spinal muscular atrophy (SMA) patients.
Materials and Methods: Lymphoblastoid cell lines were established from one type I and two type III SMA
patients. Following treatment of the cell lines by HDAC inhibitors, the levels of survival motor neuron 2
(SMN2) gene full length (fl-SMN2) transcripts were assessed by both standard and real time RT-PCR. To
determine the levels of SMN protein, Western blot analysis was performed.
Results: NB and PB, which are known to be effective in SMA fibroblasts, did not increase the levels of fl-SMN2
transcripts or protein in lymphoblastoid cell lines.
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Conclusions: Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines may not be suitable for studying
the effect of at least some HDAC inhibitors on SMN2 gene expression.
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Lenfoblastoid Hücre Hatlar›
Histon Deasetilaz Inhibitörleri ile Artt›r›lan SMN Gen Ekspresyon Çal›ﬂmalar›
‹çin Uygun mudur?
Amaç: Histon deasetilaz (HDAC) inhibitörleri s›n›f›na giren sodyum bütirat (NB) ve fenil bütirat (PB) adl›
bileﬂiklerin spinal müsküler atrofi (SMA) hastalar›ndan oluﬂturulan lenfoblastoid hücre hatlar› üzerindeki
etkisini araﬂt›rmak
Yöntem ve Gereç: Bir SMA tip I ve iki SMA tip III hastas›n›n lenfoblastoid hücre hatlar› oluﬂturuldu. HDAC
inhibitör uygulamas›n› takiben, survival motor neuron 2 (SMN2) genine ait fl-SMN2 transkript miktar› hem
standart hem de real time RT-PCR yöntemi ile saptand›. SMN protein miktar›ndaki de¤iﬂikli¤i incelemek
amac›yla Western blot analizi gerçekleﬂtirildi.
Bulgular: SMA fibroblastlar›nda etkili oldu¤u bilinen sodyum bütirat ve fenil bütirat›n, lenfoblastoid hücre
hatlar›nda fl-SMN2 transkript ve protein miktar›n› artt›rmad›¤› saptand›.
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Sonuç: HDAC inhibitörlerinin SMN2 gen ekspresyonu üzerindeki etkisinin araﬂt›r›lmas›nda Epstein-Barr Virus
(EBV) transformasyonu ile oluﬂturulan lenfoblastoid hücre hatlar›n›n uygun olmad›¤› sonucuna var›lm›ﬂt›r.
Anahtar Sözcükler: Spinal müsküler atrofi, survival motor neuron geni, histon deasetilaz inhibitörleri, tedavi
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Introduction
Spinal muscular atrophy (SMA) is a childhood
autosomal recessive disorder that is characterized by
degeneration of alpha motor neurons in the anterior horn
of the spinal cord. The disorder has an incidence of
1/6,000-1/10,000 live births (1). The Survival Motor
Neuron (SMN1) gene, located in 5q13, is responsible for
this condition. Homozygous absence of exon 7 of the
SMN1 gene can be detected in 95-98% of the patients
(2,3). In the same region, a second gene (SMN2) is
present, which is almost identical to SMN1. The main
difference between the two genes is a C-to-T transition in
exon 7 of SMN2, which disrupts a SF2/ASF dependent
exonic splicing enhancer (ESE), causing exon skipping,
and the prevalent production of transcripts lacking exon
7 (∆7) and of truncated protein isoforms (4). The
number of SMN2 copies is highly variable in the
population. The clinical phenotype can range from severe
to mild (type I to type III); the severity of the disease is in
part modulated by the number of SMN2 genes, with
higher copy number related to milder phenotypes (5).
To date, no cure for SMA is available. Recently,
efforts have been made to investigate the possibility of a
pharmacological approach to SMA aimed at increasing the
synthesis of full length SMN2 (fl-SMN2) mRNA and
protein. Different classes of compounds have been tested
and it has been shown that histone deacetylase (HDAC)
inhibitors are effective in increasing SMN2 gene
expression both in vivo and in vitro, although with
variable results from patient to patient and in different
cell types (6-12). Further studies on various cell types will
provide useful information for the treatment of SMA.
Lymphoblastoid cell lines are immortal lines that can
easily be obtained from blood lymphocytes and provide
large amounts of biological materials such as RNA and
protein (13). In this study, we investigated whether
lymphoblastoid cell lines can be used as a tool for
identifying therapeutic agents for SMA and analyzed the
effect of sodium butyrate (NB) and phenylbutyrate (PB)
on SMN2 gene expression in lymphoblastoid cell lines.

Materials and Methods
Establishment of Lymphoblastoid Cell Lines
Epstein-Barr virus (EBV)-transformed lymphoblastoid
cell lines were established from one type I and two type
III SMA patients. Patients were confirmed to have
8
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homozygous deletions of exons 7 and 8 of the SMN1
gene. Informed consent was obtained from the families.
Lymphocytes were isolated from heparinized peripheral
blood by Ficoll-Histopaque separation (Biochrom,
Germany). The buffy coat interface was collected and cell
pellet was resuspended in 2 ml RPMI 1640 medium with
20% heat inactivated fetal bovine serum, 100 U/ml
penicillin and 100 mg/ml streptomycin, and of an equal
volume of EBV-containing medium. After O/N incubation,
500 ng of cyclosporin A were added per ml of culture
medium (14). Flasks were incubated in a humidified
37°C, 5% CO2 incubator.
This study was approved by the Research Ethics
Committee of Hacettepe University, Faculty of Medicine
(TBK 02/ 4-8).
Treatment of Lymphoblastoid Cell Lines with
Sodium Butyrate (NB) and Phenylbutyrate (PB)
For transcript analysis, cell cultures from one SMA
type I (Patient 1) and one SMA type III (Patient 2) patient
were incubated with 0.05, 0.5 and 5 mM NB
(CH3CH2CH2COONa, Merck, Germany) for 4, 8, 24 and
32 h, and the amount of SMN2 mRNA was determined by
densitometric analysis (6).
Cell cultures from two type III patients (Patients 2 and
3) were incubated with 0.05, 0.5, 1, 2 and 5 mM PB
(C6H5(CH2)3COOH, Fluka Chemika, Switzerland) for 8 h,
and transcript analysis was performed by real time
reverse transcriptase-polymerase chain reaction (RTPCR) (7). These two cell lines were also treated with 2
mM PB for different time intervals (8, 16, 24 and 48 h)
for protein analysis. The medium was changed every 24
h and in case of 48 h treatment, PB was added after 24
h.
Analysis of SMN2 mRNA from Lymphoblastoid Cell
Lines
Total RNA was extracted from treated and untreated
cell lines using the RNeasy Mini Kit (Qiagen, Germany).
Two µg of RNA were used for first strand cDNA synthesis
by using the ImpromII RT System kit (Promega,
Germany) according to the manufacturer’s instructions.
For semiquantitative standard PCR, the following
conditions were used: 22 cycles at 95 ºC for 15 s, 56 ºC
for 30 s, 72 ºC for 45 s using primers within SMN2 exon
6 (5′-CTCCCATATGTCCAGATTC-TCTTGATGATGC-3′ and
exon 8 (5′-ACTGCCTCACCACCGTGCTGG-3′) (6).
Densitometric measurements were carried out with gel
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analyzer and Documentation System (Biodoc, Biometra,
Germany). PCR products were visualized on a 4%
agarose gel by ethidium bromide staining.
Real time RT-PCR was performed using the ABI
PRISM 7700 Sequence Detector System (Applied
Biosystems, Italy) as described by Andreassi et al. (7). The
relative amount of transcripts was calculated by using the
threshold cycle (Ct) method, comparing SMN to two
internal standards such as glyceraldehyde phosphate
dehydrogenase (GAPDH, Applied Biosystems) and ß-actin
(Applied Biosystems). The reactions were performed in
triplicate and averaged. SMN Ct values were corrected for
GAPDH and β-actin Ct values using the ∆∆Ct method. The
experiments were repeated twice and untreated
lymphoblastoid cell lines were provided as a control. The
statistical analysis was done with a non-parametric
Kruskal-Wallis test (SPSS program 11.5). P values ≤0.05
were considered significant.
Analysis of SMN Protein Levels
Protein samples were extracted from treated and
untreated cell lines by standard blending buffer. Western
blot analysis was performed as described by Andreassi et
al. (7). Membranes were probed with anti-SMN (dilution
1/5000, Transduction Laboratories, Italy), primary
antibody 1 h at room temperature. After washing,
membranes were incubated with the anti-mouse
horseradish peroxidase-conjugated secondary antibody
(dilution 1/2000) for 1 h at room temperature and
visualized using chemiluminescence (ECL, Amersham,
UK). Membranes were reprobed with the anti-actin
polyclonal primary antibody (dilution 1/2000, SigmaAldrich, Italy), and anti-rabbit horseradish peroxidaseconjugated secondary antibody (dilution 1/2000,
Amersham, UK).
The intensity of Western blot bands was measured by
densitometry (Scion Image Software, Maryland, USA).
SMN/ß-actin density ratios were normalized to untreated
samples, which were used as a control. For each sample,
three different Western blots were performed.

PB, which has a longer half-life in vivo compared to
NB, has been reported to be more effective in increasing
fl-SMN2 transcripts in SMA type III than type I fibroblasts
(7). Therefore, we treated two SMA type III
lymphoblastoid cell lines with PB. The effect of different
concentrations and treatment durations of PB on fl-SMN2
transcripts are shown in Figure 1. Only slight variations
in fl-SMN2 transcript levels, which were not statistically
significant, were found (P > 0.05). To determine
whether PB has an effect on SMN protein level, we
performed Western blot analysis. No increase in SMN
protein levels was observed in lymphoblastoid cell lines
compared to untreated controls. The effect of PB on SMN
protein level is shown in Figure 2. Thus, neither NB nor
PB treatment modified the levels of fl-SMN2 transcripts
or protein in lymphoblastoid cell lines.
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Cell lines from one type I (Patient 1) and one type III
(Patient 2) patient were treated with NB and the amount
of fl-SMN2 transcripts was determined by densitometric
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shown in Table 1. No increase in transcript levels was
found, suggesting that EBV-transformed cell lines may
not be responsive to NB. Since NB did not increase flSMN2 transcript levels, real time RT-PCR and Western
blot analysis were not performed.

increase in full length SMN2
transcripts (%)

No: 1

increase in full length SMN2
transcripts (%)

Vol: 38

5

Patient 2
Patient 3

8
16
24
phenyl butyrate incubation period (hrs)
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Figure 1. The effect of phenylbutyrate on full length SMN2 transcripts
as determined by real time PCR.
a. Effect of different concentrations of phenylbutyrate.
b. Effect of different treatment durations of phenylbutyrate.
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Table 1. The effect of sodium butyrate on full length (FL) SMN2 RNA, ∆7 SMN2 RNA and FL/∆7
as determined by densitometric analysis.
Sodium butyrate concentration (mM)
SMA lymphoblastoid cell lines

Patient 1

Patient 2

0

0.05

0.5

5

4h

FL
∆7
FL/∆7

13
12
1.1

10
10
1

13
13
1

11
15
0.7

8h

FL
∆7
FL/∆7

20
14
1.4

17
14
1.2

15
13
1.2

16
15
1.1

24 h

FL
∆7
FL/∆7

16
14
1.1

21
16
1.3

15
13
1.2

13
12
1.1

32 h

FL
∆7
FL/∆7

22
22
1

23
23
1

24
25
1

22
22
1

4h

FL
∆7
FL/∆7

60
66
0.9

62
67
0.9

66
69
1

63
69
0.9

8h

FL
∆7
FL/∆7

14
13
1.1

15
13
1.2

17
14
1.2

15
14
1.1

24 h

FL
∆7
FL/∆7

15
14
1.1

14
13
1.1

15
13
1.2

13
12
1.1

32 h

FL
∆7
FL/∆7

30
23
1.3

27
21
1.3

25
19
1.3

14
13
1.1

FL: full length

Patient 3

}
}
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48h
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NT
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NT
42 kDa Actin

39 kDa SMN

Figure 2. The effect of 2 mM phenyl butyrate on SMN protein as determined by Western blot
analysis.
NT: Non–treated.
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Discussion
Currently, the most promising therapeutic strategy is
to increase fl-SMN2 gene expression by HDAC inhibitors.
These compounds may directly activate the SMN2
promoter or alter the SMN2 splicing pattern (15). HDAC
inhibitors are known to affect the expression of 2-5% of
genes through the hyperacetylation of histones, which
alters the chromatin structure of DNA and makes it
accessible to the transcriptional machinery. In addition to
their effect on transcription, HDAC inhibitors possess
diverse biological activities (16). Well- known HDAC
inhibitors such as NB and PB are approved by the Food
and Drug Administration for application in the treatment
of various disorders (17,18). A few studies showed that
these compounds enhanced growth inhibition,
morphological changes, apoptosis, cytokine production,
and oncogene and HLA expressions in lymphoblastoid cell
lines (19-22).
In this study, we hypothesized whether SMA
lymphoblastoid cell lines would be suitable in increasing
SMN expression after NB and PB treatment. We
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demonstrated that treatment of lymphoblastoid cell lines
did not result in an increase in fl-SMN2 transcripts or
protein. Although we analyzed a few cell lines, our data
suggest that lymphoblastoid cell lines may not be a
suitable in vitro model for studying the effect of the
HDAC inhibitors on SMN expression. Barth et al. (23)
demonstrated that EBV nuclear antigen 2, which is
essential for viral transformation of lymphocytes, binds
to SMN protein. The interaction between these two
proteins may explain why fl-SMN2 expression is not
increased in lymphoblastoid cell lines after HDAC inhibitor
treatment. The explanation for our findings remains
elusive, although it can be hypothesized that EBV
transformation modifies the responsiveness of cell
cultures at least to some HDAC inhibitors.
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